Juan Andres - 09 Nov 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
09 Nov 2022
Net transactions value
-$314,933
Form type
4
Filing time
14 Nov 2022, 15:41:08 UTC
Previous filing
04 Nov 2022
Next filing
18 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $0 +435 +3.8% $0.000000 12,001 09 Nov 2022 Direct F1
transaction MRNA Common Stock Options Exercise $41,860 +2,000 +17% $20.93* 14,001 09 Nov 2022 Direct F2
transaction MRNA Common Stock Sale $325,000 -2,000 -14% $162.50 12,001 09 Nov 2022 Direct F2
transaction MRNA Common Stock Sale $31,793 -192 -1.6% $165.59 11,809 10 Nov 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -435 -4% $0.000000 10,413 09 Nov 2022 Common Stock 435 $0.000000 Direct F1, F4
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2,000 -0.91% $0.000000 217,025 09 Nov 2022 Common Stock 2,000 $20.93 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F3 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.
F5 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer